Search alternatives:
teer decrease » greater decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 661 - 680 results of 102,574 for search '(( 5 ((c decrease) OR (a decrease)) ) OR ( 5 ((teer decrease) OR (mean decrease)) ))', query time: 1.71s Refine Results
  1. 661
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 662
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 663
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 664
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 665
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 666
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 667
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 668
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 669
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 670
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 671
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 672
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 673
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 674
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 675
    Knockdown of Tsg101 and Alix decrease the production of infectious OROV.

    Knockdown of Tsg101 and Alix decrease the production of infectious OROV. by Natalia S. Barbosa (5172338)

    Published 2018
    Save to List
    Saved in:
  16. 676
    Su(H) and RBPJ AOS variants decrease DNA binding.

    Su(H) and RBPJ AOS variants decrease DNA binding. by Ellen K. Gagliani (11478756)

    Published 2022
    Save to List
    Saved in:
  17. 677
    MML-induced autophagy is associated with the decrease in p53 levels.

    MML-induced autophagy is associated with the decrease in p53 levels. by Hyun-Kyu An (498473)

    Published 2014
    Save to List
    Saved in:
  18. 678
    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart.

    Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart. by Craig Bolte (299486)

    Published 2013
    “…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
    Save to List
    Saved in:
  19. 679
    <i>dSmad2</i> mutant clones display increased dILP2 in IPCs and decreased dILP5 in CPCs.

    <i>dSmad2</i> mutant clones display increased dILP2 in IPCs and decreased dILP5 in CPCs. by Samuel L. Goldsmith (5533913)

    Published 2023
    Save to List
    Saved in:
  20. 680
    The effects of NAC on the decreased number of myotube formations caused by arecoline.

    The effects of NAC on the decreased number of myotube formations caused by arecoline. by Yi-Xuan Li (6633845)

    Published 2022
    Save to List
    Saved in:

Search Tools: